anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive anastrozole PO QD for 56-70 days (8-10 weeks). Patients with E1 \>= 1.3 pg/ml and E2 \>= 0.5 pg/ml continue to receive anastrozole PO QD for another 56-70 days (8-10 weeks). Patients then receive letrozole PO QD for 8-10 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
The invention belongs to the technical field of medicines, and develops and verifies a ginkgo extract for treating osteoarthritis. Through early-stage bioinformatics screening, predicting the extract monomer of the traditional Chinese medicine ginkgo: the ginkgolide has potential anti-arthritis function. In vitro experiments, the ginkgolides with different concentrations intervene human chondrocytes under an arthritis environment, and the change of the steady state of the chondrocyte extracellular matrix is detected; in vivo experiments the effect of ginkgolide treatment on the cartilage homeostasis of mice after trauma was observed by intraperitoneal injection of ginkgolide. The ginkgolide obtained by the invention has a strong protection effect on cartilage metabolic balance. The in vivo animal model further verifies that ginkgolides can relieve the degeneration of articular cartilage after injury. The invention provides new theoretical and experimental references for the current research on osteoarthritis treatment by traditional Chinese medicine monomers, overcomes the defect of poor treatment effect of the existing osteoarthritis, and widens the clinical treatment prospect of the traditional Chinese medicine monomers in osteoarthritis.
The present invention is directed to a fungal extract comprising antimicrobial activity. More specifically, the fungus used belongs to the family Polyporaceae, especially genus Trametes, namely Trametes sp. 11 E4. Specifically, the extract demonstrated activity against bacteria such as R. sonalacearum, E. coli, S. aureus, B. cereus and S. anatum. It also may be used in compositions, such as pest control compositions, which would be useful in agriculture, i.e. treating bacterial wilt and medicine.
A second group consisted of twenty-two children (11 females and 11 males; a mean age of 5.20 ± 0.36 years) were selected to act as a control sample and received no dental treatment. MOBF was recorded in these subjects at T0 and T5 (6 months after).
PURPOSE: A cosmetic composition containing Broussonetia kazinoki Sieb extract with stabilized nano liposome for skin whitening is provided to suppress melanogenesis and pigmentation. CONSTITUTION: A cosmetic composition for skin whitening contains stabilized Broussonetia kazinoki Sieb extract as an active ingredient. The composition is used for suppressing melanogenesis. The content of the Broussonetia kazinoki Sieb extract is 0.001-50 weight% based on total weight of the composition. A method for manufacturing Broussonetia kazinoki Sieb extract comprises: a step of drying Broussonetia kazinoki Sieb and slicing; and a step of performing cold infusion, maceration with warm water, or percolation of the sliced Broussonetia kazinoki Sieb using polar solvent of water, ethanol, butanol, or acetone, non-polar solvent of ether, hexane, benzene, chloroform, or ethyl acetate, or soybean oil. The infusion and percolation are performed for 12-96 hours and maceration is performed for 0.5-24 hours.
PCT No. PCT/GB95/01426 Sec. 371 Date Apr. 4, 1997 Sec. 102(e) Date Apr. 4, 1997 PCT Filed Jun. 19, 1995 PCT Pub. No. WO95/35097 PCT Pub. Date Dec. 28, 1995Provided are biodegradable microparticles, which exhibit a linear release profile of active agent, and methods for making the microparticles. The microparticles include a mixture of a biodegradable polymer, a water soluble polymer, and an active agent. Preferred biodegradable polymers include lactide homopolymers or copolymers of lactide and glycolide, and preferred water soluble polymers include poly(ethylene glycol) (PEG) or PEG copolymers. The microparticles are made using an emulsion/solvent extraction method, in which the continuous phase of the secondary emulsion contains an organic solvent that is miscible with the organic solvent in the primary emulsion.
FIELD: organic chemistry. SUBSTANCE: invention relates to new pyranone compounds that can be used for inhibition of retroviruses in human cells infected with indicated retroviruses. Invention describes pyranone compounds of the general formula (I)   where values R 1 ,R 2 ,R 3 ,R 10 ,R 11  are indicated in point 1 of the claim. Invention describes also a pharmaceutical composition based on the above indicated compounds of the indicated prescription. EFFECT: enhanced effectiveness of compounds and composition. 25 cl, 56 dwg, 4 tbl, 116 ex
Trauma is still the leading cause of death in young adults and a major cause of morbidity and mortality at all ages.(1,2). Polytrauma is defined as injury to several physical regions or organ systems, where at least one injury or the combination of several injuries are life threatening with the severity of injury being equal or \>16 on the scale of the Injury Severity Score (ISS). Prediction of mortality in trauma patients is an important part of trauma care (3). The trauma and injury severity score (TRISS) and Acute Physiology and Chronic Health Evaluation IV (APACHE IV) are used commonly to predict injury severity and risk of mortality. Although it is regarded as the international standard in trauma scoring, it has complex calculating and incorporates the Glasgow Coma Scale (GCS) for neurological evaluation (4). Regardless of the accuracy of trauma scores, is based on an anatomical description of every injury and cannot be assigned to the patients until a full diagnostic procedure has been performed(5) . Many studies have revealed alteration in glucose metabolism in trauma and proportional relation of its high level to the degree of injury (6). hyperglycaemia is associated with similar complications as uncontrolled diabetes, including an increased mortality, an increased number of infectious complications, and poor wound healing. The presence of elevated blood glucose also impedes normal host defences against infection and impairs the normal inflammatory response (7.8).

* Therefore, this study will be conducted to compare between alterations in easy and rapid predictors as glucose level, base deficit and lactate and difficult and slow predictors as TRISS and APACHE IV. So, it could be considered an early and easy rapid predictor of outcome .
Mafenide Acetate 5% Topical Solution

Directions for Preparation of the Solution

Mafenide Acetate 5% Topical Solution is supplied as a sterile powder and is to be reconstituted with Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP. Aseptic techniques should be observed during preparation of the solution. Premeasured quantities of 50 g of Mafenide Acetate powder are provided in sterile packets. The entire quantity of Mafenide Acetate pouch should be emptied into a suitable container which contains 1000 mL of Sterile Water for Irrigation, USP or 0.9% Sodium Chloride Irrigation, USP and mixed until completely dissolved. The reconstituted solution may be held up to 28 days after preparation if stored in unopened containers. ONCE A CONTAINER IS OPENED, ANY UNUSED PORTION SHOULD BE DISCARDED AFTER 48 HOURS. Store the reconstituted solution at 20° to 25°C (68° to 77°F). Limited storage periods at 15° to 30°C (59° to 86°F) are acceptable. Not for Injection-For Topical Use Only.

Directions for Use of the Solution

The grafted area should be covered with one layer of fine mesh gauze. An eight-ply burn dressing should be cut to the size of the graft and wetted with Mafenide Acetate 5% Topical Solution using an irrigation syringe and/or irrigation tubing until leaking is noticeable. If irrigation tubing is used, the tubing should be placed over the burn dressing in contact with the wound and covered with a second piece of eight-ply dressing. The irrigation dressing should be secured with a bolster dressing and wrapped as appropriate. The gauze dressing should be kept wet. In clinical studies, this has been accomplished by irrigating with a syringe or injecting the solution into the irrigation tubing every 4 hours or as necessary. If irrigation tubing is not used, the gauze dressing may be moistened every 6-8 hours or as necessary to keep wet.

Wound dressings may be left undisturbed, except for the irrigations, for up to five days. Additional soaks may be initiated until graft take is complete. Maceration of skin may result from wet dressings applied for intervals as short as 24 hours. Treatment is usually continued until autograft vascularization occurs and healing is progressing (typically occurring in about 5 days). Safety and effectiveness have not been established for longer than 5 days for an individual grafting procedure.

If allergic manifestations occur during treatment with Mafenide Acetate 5% Topical Solution, discontinuation of treatment should be considered. If acidosis occurs and becomes difficult to control, particularly in patients with pulmonary dysfunction, discontinuing the soaks with the Mafenide Acetate solution for 24 to 48 hours may aid in restoring acid-base balance (see PRECAUTIONS section). Dressing changes and monitoring the site for bacterial growth during this interruption should be adjusted accordingly.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to vertebrology, and can be applied for treatment of intervertebral disk hernia. For this purpose treatment is carried out in, at least, two stages. At the first stage carried out is, at least, one course of complex therapy, directed at maximal softening of disk hernia, at suppression of inflammatory response and reduction of pain syndrome. At the second stage carried out is, at least, one session of focused extracorporal shock-wave therapy, directed at the area of pathological focus of intervertebral disk. ^ EFFECT: method insures high efficiency, even in conditions of ambulatory treatment of patients, in absence of scar changes or other treatment complications. ^ 12 cl, 5 ex, 1 tbl
Sexually transmitted diseases (STDs) are a global concern because approximately 1 million new cases emerge daily. Most STDs are curable, but if left untreated, they can cause severe long-term health implications, including infertility and even death. Therefore, a test enabling rapid and accurate screening and genotyping of STD pathogens is highly awaited. Herein, we present the development of the DNA-based 6STD Genotyping 9G Membrane test, a lateral flow strip membrane assay, for the detection and genotyping of six STD pathogens, including Trichomonas vaginalis, Ureaplasma urealyticum, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma hominis, and Mycoplasma genitalium. Here, we developed a multiplex PCR primer set that allows PCR amplification of genomic materials for these six STD pathogens. We also developed the six ssDNA probes that allow highly efficient detection of the six STD pathogens. The 6STD Genotyping 9G Membrane test lets us obtain the final detection and genotyping results in less than 30 m after PCR at 25 °C. The accuracy of the 6STD Genotyping 9G membrane test in STD genotyping was confirmed by its 100% concordance with the sequencing results of 120 clinical samples. Therefore, the 6STD Genotyping 9G Membrane test emerges as a promising diagnostic tool for precise STD genotyping, facilitating informed decision-making in clinical practice.
Guanfacine is commonly used for the treatment of tics in children with Tourette Disorder, but neither the immediate release compound nor the new extended release formulation have been evaluated for tics as a primary outcome. This pilot study is not designed to demonstrate efficacy of extended release guanfacine in the treatment of tics in children with TD. Rather, the goal of this trial is to determine whether extended release guanfacine warrants further study in a large scale trial. Immediate-release guanfacine is frequently used in children with TD, but dosing, time to effect and adverse effects with the new extended release guanfacine are unknown. The use of placebo in this trial reduces bias in the measurement of outcomes because it ensures blindness in the parent and clinician ratings.

This is a three-site, investigator-initiated, randomized, double-blind, placebo-controlled, parallel-group study. Subjects who show a positive response to extended release guanfacine in the 8-week double-blind phase will continue on the the drug in an 8-week extension phase. Subjects who are randomly assigned to placebo and do not show improvement will be offered 8-weeks of open-label treatment with Intuniv.
BACKGROUND: Distinguishing self-limiting ('trivial') from potentially consequential spinal pain in childhood and adolescence is crucial to prevent over- or under-medicalization. The aim of this study was to stratify participants for severity of spinal pain and to investigate associations of pain severity with potential consequences of pain and some psychophysical and clinical factors.
METHODS: In 2020 and 2021, children and adolescents took part in a voluntary population-based spine screening event across Switzerland organized by the Swiss Chiropractors Association. The screening consisted of a questionnaire (14 questions) based on the Young Spine Questionnaire and a clinical examination by a chiropractor. Three subgroups of pain severity [no pain (including mild, occasional pain), one-sited moderate pain, one-sited severe or moderate/severe pain at multiple sites of the spine] were formed by combining the self-reported measures for pain intensity and pain frequency for two recall periods (lifetime, last week) according to literature. Multivariable logistic regression analyses were conducted to determine the associations between pain severity and potential pain consequences (impact of spinal pain on health and seeking medical advice because of spinal pain), as well as between pain severity and some psychophysical factors (head and/or belly pain, sleep problems, daytime tiredness) and clinical measures [trunk symmetry (rib hump), trunk muscle endurance (plank position)].
RESULTS: Of all participants (N = 457; 6-16 years; mean age = 10.9 ± 3.0 years; 220 boys), those with most severe spinal pain and with one-sited moderate pain in the last week had higher odds for reporting an impact of spinal pain on their health (OR = 13.5, 95%CI = 4.9-36.8; OR = 4.7, 95%CI = 1.5-14.4) and for searching medical advice because of spinal pain (OR = 11.6, 95%CI = 4.5-30.1; OR = 3.9, 95%CI = 1.6-9.2). Headache and/or belly pain (OR = 2.6, 95%CI = 1.2-5.5) and daytime tiredness (OR = 3.2, 95%CI = 1.3-7.9) increased the odds for having most severe pain compared to having no pain. The clinical measures were not associated with pain severity.
CONCLUSION: Stratification by pain severity, particularly when asked for pain in the last week, might help to minimize over- and under-medicalization of spinal pain in childhood and adolescence. Prospective studies are needed to clarify the relevance of the investigated clinical tests in the context of adolescent spinal pain.
It is important to individualize the dosage of triazolam tablets for maximum beneficial effect and to help avoid significant adverse effects.

The recommended dose for most adults is 0.25 mg before retiring. A dose of 0.125 mg may be found to be sufficient for some patients (e.g., low body weight). A dose of 0.5 mg should be used only for exceptional patients who do not respond adequately to a trial of a lower dose since the risk of several adverse reactions increases with the size of the dose administered. A dose of 0.5 mg should not be exceeded.

In geriatric and/or debilitated patients the recommended dosage range is 0.125 mg to 0.25 mg. Therapy should be initiated at 0.125 mg in these groups and the 0.25 mg dose should be used only for exceptional patients who do not respond to a trial of the lower dose. A dose of 0.25 mg should not be exceeded in these patients.

As with all medications, the lowest effective dose should be used.
The invention relates to traditional Chinese medicine and especially provides a health-care product for preventing and treating the emaciation of a human body. The content of a capsule comprises the following components: 15 parts of traditional Chinese medicine extract, 30-40 parts of wild rose honey, 10 parts of trichosanthes root, 10 parts of lilium brownie, 10 parts of turmeric, 30 parts of peony seed oil, and 5-10 parts of blueberry. The traditional Chinese medicine extract is prepared by the following raw materials in weight part: 8 parts of dendrobium, 8 parts of inula Britannica, 6 parts of semen astragali complanati, 5-9 parts of agapetes mannii hemsl, 6-9 parts of sopubia trifida buch, 5-7 parts of Hedyotis capitellata, 7-9 parts of carolina fanwort and 7-10 parts of hispid arthraxon. The health-care product has the efficacies of enhancing the immunity of a human body, promoting the blood circulation, strengthening the spleen and the stomach, and benefiting the Qi and the blood, so that the curative effect of the health-care product in treating the emaciation of the human body is obvious. In treating the emaciation of the human body, the health-care product can both resolve the current problems and eliminate the root causes. Meanwhile, the health-care product is fast in efficacy, good in therapeutic effect, and free of any toxic or side effect. The effective rate of the health-care product is high up to 100%.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes (T2DM) with chronic kidney disease (CKD). This class of medication has demonstrated promising results in reducing albuminuria, preserving estimated glomerular filtration rate (eGFR), and mitigating cardiovascular (CV) risk, making them potential therapeutic options for individuals with CKD. The kidney protective effects of GLP-1RAs extend beyond glycaemic control, and are thought to be attributed to their anti-inflammatory, antioxidant, and natriuretic properties. Despite these promising findings, the use of GLP-RAs has yet to be definitively shown to slow progression to chronic kidney failure, or reduce CV and kidney related death in people with T2DM and CKD. The Research Study to See How Semaglutide (a once weekly subcutaneous administered GLP-1RA) Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease (FLOW trial) was recently stopped because of efficacy. The primary end point for the FLOW trial consists of a composite endpoint of (i) onset of chronic kidney failure; (ii) death from kidney failure; (iii) cardiovascular death; and (iv) onset of a persistent ≥50% reduction in eGFR from baseline. It has also been reported by the sponsors of the trial that the primary end point of the trial was reduced by 24% with both CKD and CV outcomes contributing to risk reduction. In anticipation of the results of the FLOW trial being published, we review the current evidence surrounding kidney outcomes and proposed kidney protective pathways associated with GLP-1RA use.
The invention discloses a kind of Chinese medicine preparation for the treatment of senile hypothyroidism.Senile hypothyroidism " hypothyroidism " belongs to the traditional Chinese medical science " asthenia " category, and motherland's medical science thinks that primary disease is how not enough by natural endowment, loses the day after tomorrow and supports, or internal injury of being overworked for a very long period, and prolonged illness imbalance causes kidney qi, deficiency of spleen-QI, then caused by deficiency of spleen-YANG and kidneyYANG.The present invention selects to have nourishing YIN and invigorating YANG, kidney and spleen invigorating, the Chinese medicine Rhizoma Tupistrae Chinensis of blood circulation promoting and blood stasis dispelling, Rhizoma Polygonati Cirrhifolii, Radix Tylophorae arenicolae, Herba Silenes conoideae, Lignum corni macrophyllae, Fructus Pandani tectorii, Pleurotus citrinopileatus Sing (Pleurotus ulmarius (Bull. Ex Fr.) Quel.), Flos Caraganae intermediae, Folium Ilicis Cornutae, Abacopteris multilineata(Wall.) Ching (Pronephrium multilineatum (Wall.) ching, decocting becomes decoction, through clinical trial, total effective rate reaches 93.3%, curative effect highly significant.
PURPOSE: To medicinal composition useful of the treatment of psoriasis, phlebitis, atopic dermatitis, etc., which contains, as an active ingredient, ester of an ω-3 polyunsaturated aliphatic acid, and has ability to avid the evolution of unpleasant and undesirable odor. CONSTITUTION: The composition contains, as an active ingredient, 10-40 wt.% of a 1-3C alkyl ester of an ω-3polyunsaturated aliphatic acid (e.g. ethyl ester of cis-5,8,11,14,17-eicosapentaenoic acid). Further, preferably, the composition contains 0.3-5 wt.%, based on the ester, of antioxidant derived from phenol (e.g. a butylated hydroxyanisole) and 1-20 wt.%, based on the ester, of triehtyl citrate. Addition of the antioxidant into the composition prevents the decomposition of the ester and thus inhibits the evolution of unpleasant and undesirable odor. Activity of the antioxidant is increased by the addition of the triethyl citrate.
NEW MATERIAL:A beta-tetrazole-substituted alanine derivative of formula I (R is alkyl or aryl; X is SO2, So or O; A is H or amino-protecting group; B is OH or carboxyl-protecting group). EXAMPLE:S-(1-methyltetrazole-5-yl)-N-carbobenzoxy-D-cysteine-t-butyl ester S,S-dioxide. USE:A compound of formula I wherein A is H and B is OH is useful as an agent for inhibitng biosynthesis of bacterial cell wall. The above compound and a compound wherein A is amono-protecting group and B is carboxyl-protecting group are synthetic intermediates for antibacterial agent. PREPARATION:A sulfone compound of formula III which is one of the compounds of formula I or a sulfoxide compound of formula IV (the case that A is H or B is OH is excluded in the compounds of formula II-IV) can be produced e.g. by oxidizing a cysteine derivative of formula II in the presence of an oxidizing agent.
Amlexanox is an anti-inflammatory and anti-allergic agent used clinically for the treatment of aphthous ulcers, allergic rhinitis, and asthma. Recent studies have demonstrated that amlexanox, a selective inhibitor of IkB kinase epsilon (IKKε) and TANK-binding kinase 1 (TBK1), suppresses a range of diseases or inflammatory conditions, such as obesity-related metabolic dysfunction and type 2 diabetes. However, the effects of amlexanox on neuroinflammatory responses to amlexanox have not yet been comprehensively studied. In this study, we investigated the novel therapeutic effect of amlexanox on LPS-induced neuroinflammation in vivo, and intraperitoneal injection of amlexanox markedly reduced LPS-induced IKKε levels, proinflammatory cytokines, and microglial activation, as evidenced by ionized calcium-binding adapter molecule 1 (Iba1) immunostaining. Furthermore, amlexanox significantly reduced proinflammatory cytokines and chemokines in LPS-induced bone marrow-derived macrophages (BMDM), murine BV2, and human HMC3 microglial cells. This data provided considerable evidence that amlexanox can be used as a preventive and curative therapy for neuroinflammatory and neurodegenerative diseases. In terms of mechanism aspects, our results demonstrated that the anti-inflammatory action of amlexanox in BV2 microglial cells was through the downregulation of NF-κB and STAT3 signaling pathways. In addition, the combination of amlexanox and SPI (a STAT3 selective inhibitor) showed high efficiency in inhibiting the production of neurotoxic and pro-inflammatory mediators. Overall, our data provide rational insights into the mechanisms of amlexanox as a potential therapeutic strategy for neuroinflammation-related diseases.
Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.